These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8684530

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD, D'Haese PC, Pires C, Lamberts LV, Simões J, De Broe ME.
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [Abstract] [Full Text] [Related]

  • 6. Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
    Canavese C, Gurioli L, D'Amicone M, Cardelli R, Caligaris F, Bongiorno P, Arnaud A, Mattiello G, Marchiori M.
    Nephron; 1992 Jan; 60(4):411-7. PubMed ID: 1584315
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M, Andrés A, de la Serna J, Ruilope LM, Nieto J, Estenoz J, Millet VG, Arnaiz F, Rodicio JL.
    Nephrol Dial Transplant; 1987 Jan; 2(4):243-7. PubMed ID: 3118265
    [Abstract] [Full Text] [Related]

  • 14. Chromatographic studies of aluminum-desferrioxamine complex in uremic patients.
    Canavese C, Pacitti A, Salomone M, Pramotton C, Segoloni G, Bedino S, Testore G, Lamon S, Vercellone A.
    ASAIO Trans; 1986 Jan; 32(1):367-9. PubMed ID: 3778736
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function.
    D'Haese PC, Lamberts LV, Verpooten GA, Vaneerdeweg W, Jurgens A, Arakelian S, Babloyan A, Digenis P, Tjalma W, De Broe ME.
    Kidney Int; 1994 Jan; 45(1):76-84. PubMed ID: 8127024
    [Abstract] [Full Text] [Related]

  • 17. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P.
    Ann N Y Acad Sci; 2005 Jan; 1054():155-68. PubMed ID: 16339661
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Concomitant iron and aluminum mass transfer following deferoxamine infusion during hemofiltration.
    Canavese C, Salomone M, Pacitti A, Mangiarotti G, Thea A, Dogliani M, Serra A.
    Am J Kidney Dis; 1991 Feb; 17(2):179-84. PubMed ID: 1992660
    [Abstract] [Full Text] [Related]

  • 20. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C, Armas JR, Palma A.
    Nefrologia; 2001 Feb; 21(2):174-81. PubMed ID: 11464651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.